Muscular dystrophies encompass a family of progressive genetic disorders affecting muscle strength and integrity.
Muscular dystrophies encompass a family of progressive genetic disorders affecting muscle strength and integrity. Stem-cell research investigates whether placental mesenchymal stem cells (MSCs) and fetal stem cells can integrate into damaged muscle tissue, secrete anti-inflammatory factors, and halt the cascade of degeneration characteristic of conditions like Duchenne muscular dystrophy. The approach targets both direct muscle regeneration through cell fusion and paracrine effects that reduce inflammation and fibrosis. With 26 registered trials and 4 currently recruiting participants, early-phase data suggests MSCs may slow progression, particularly when infused systemically or injected locally into affected muscles. The neuromuscular pathology — characterised by dystrophin loss and calcium dysregulation — creates a uniquely hostile environment for transplanted cells, making efficacy variable and recovery timescales extended.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €15,000–€30,000 (bioinformant.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Fetal Stem Cells |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 26 · 4 recruiting now |
For the clinic's own description, see how Stem Plus describes its Muscular Dystrophy programme ↗.
Clinical trials in muscular dystrophy have predominantly featured small cohorts and observational designs. Four recruiting studies suggest ongoing clinical investigation, though definitive efficacy data remain limited. Some trials reported modest improvements in muscle strength measures and reduced serum creatine kinase levels following MSC infusion, whilst others showed minimal functional benefit. The heterogeneity of dystrophy subtypes means outcomes differ markedly between Duchenne, Becker, and limb-girdle forms. Current evidence supports MSCs as a potential supportive therapy rather than curative, with strongest signals emerging from early-intervention cohorts. Long-term safety data are sparse, and disease progression often continues despite treatment.
Depending on assessment, a Muscular Dystrophy protocol may draw on:
Muscular dystrophy treatment costs typically range €4,000–7,500 per cycle, reflecting the need for multiple infusions and specialist neuromuscular assessment. Placental MSC sourcing and expansion for systemic administration incurs higher manufacturing expense than single-injection protocols. Disease severity and muscle group involvement influence whether local or systemic delivery is elected, affecting total cost. Many programmes require baseline and follow-up neuroimaging and strength testing, adding to overall expenses. European centres generally charge at the lower end of the range for research-protocol participation, whilst private clinics may exceed €8,000 per session.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Muscular Dystrophy cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Muscular Dystrophy.
Full Muscular Dystrophy FAQ → · Muscular Dystrophy cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка